LobbyingEnvision Healthcare lobbying by quarter
Envision Healthcare's latest lobbying report covers Q3 2026, at $10K. The four quarters Q4 2025–Q3 2026 total $831.2K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.
Envision Healthcare
- Latest quarter
- $10K
- Q3 2026 · 1 reports
- Last 12 months
- $831.2K
- Last 4 quarters
- vs last quarter
- −96.4%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $132.6K | 2 |
| Q1 2023 | $132.6K | 2 |
| Q2 2023 | $132.6K | 2 |
| Q3 2023 | $132.6K | 2 |
| Q4 2023 | $132.6K | 2 |
| Q1 2024 | $132.6K | 2 |
| Q2 2024 | $192K | 2 |
| Q3 2024 | $225K | 2 |
| Q4 2024 | $245K | 2 |
| Q1 2025 | $245K | 2 |
| Q2 2025 | $245K | 2 |
| Q3 2025 | $264K | 2 |
| Q4 2025 | $283K | 2 |
| Q1 2026 | $257.1K | 2 |
| Q2 2026 | $281.1K | 2 |
| Q3 2026 | $10K | 1 |
Policy issues the reports name
- Health issues31 reports
- Medicare and Medicaid31 reports
- Budget and appropriations3 reports
- Immigration2 reports
A report that names several issues counts once for each.
Who was lobbied
- Centers For Medicare and Medicaid Services (CMS)31 reports
- Health & Human Services, Dept of (HHS)20 reports
- HOUSE OF REPRESENTATIVES15 reports
- SENATE15 reports
- Labor, Dept of (DOL)5 reports
- Health Resources & Services Administration (HRSA)2 reports
- Homeland Security, Dept of (DHS)2 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseEnvision Healthcare | $2.6M | 15 quarters |
| McDermott+ | $460K | 16 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| JEFFREY DAVIS | 2007-2008: Staff Assistant, Sen. Dianne Feinstein. | Q3 2026 |
| PATRICK VELLIKY | Legislative Director, Congressman James B. Renacci (Feb 2014 - Sept 2015) Legislative Assistant, Congressman James B. Renacci (Jan 2011 - Oct 2011) Deputy Legislative Director, Senator Arlen Specter (April 2009 - Jan 2011) | Q3 2025 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 08/27for Q3 | McDermott+ | $10K |
| 07/29for Q2 | In-house | $251.1K |
| 07/16for Q2 | McDermott+ | $30K |
| 04/20for Q1 | In-house | $227.1K |
| 04/16for Q1 | McDermott+ | $30K |
| 01/27for Q4 2025 | In-house | $253K |
| 01/12for Q4 2025 | McDermott+ | $30K |
| 25/10/21for Q3 2025 | In-house | $234K |
| 25/10/03for Q3 2025 | McDermott+ | $30K |
| 25/07/14for Q2 2025 | In-house | $215K |
| 25/06/27for Q2 2025 | McDermott+ | $30K |
| 25/04/21for Q1 2025 | In-house | $215K |
| 25/03/31for Q1 2025 | McDermott+ | $30K |
| 25/01/21for Q4 2024 | In-house | $215K |
| 25/01/06for Q4 2024 | McDermott+ | $30K |
| 24/10/18for Q3 2024 | In-house | $195K |
| 24/10/03for Q3 2024 | McDermott+ | $30K |
| 24/07/19for Q2 2024 | In-house | $162K |
| 24/07/08for Q2 2024 | McDermott+ | $30K |
| 24/04/18for Q1 2024 | In-house | $102.6K |